-
Tytuł:
-
Antibodies to full-length and the DBL5 domain of VAR2CSA in pregnant women after long-term implementation of intermittent preventive treatment in Etoudi, Cameroon.
-
Autorzy:
-
Djontu JC; Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon.; The Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon.
Lloyd YM; John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, United States of America.
Megnekou R; Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon.; The Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon.
Seumko'o RMN; Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon.; The Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon.
Salanti A; Department of Immunology and Microbiology, Center for Medical Parasitology, University of Copenhagen, Copenhagen, Denmark.; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.
Taylor DW; John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, United States of America.
Leke RGF; The Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon.
-
Źródło:
-
PloS one [PLoS One] 2020 Aug 14; Vol. 15 (8), pp. e0237671. Date of Electronic Publication: 2020 Aug 14 (Print Publication: 2020).
-
Typ publikacji:
-
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: San Francisco, CA : Public Library of Science
-
MeSH Terms:
-
Antibodies, Protozoan/*immunology
Antigens, Protozoan/*immunology
Antimalarials/*therapeutic use
Malaria, Falciparum/*prevention & control
Pregnancy Complications, Parasitic/*prevention & control
Pyrimethamine/*therapeutic use
Sulfadoxine/*therapeutic use
Adult ; Antibodies, Protozoan/blood ; Cameroon/epidemiology ; Drug Combinations ; Female ; Humans ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Malaria/blood ; Malaria/epidemiology ; Malaria/immunology ; Malaria/prevention & control ; Malaria, Falciparum/blood ; Malaria, Falciparum/epidemiology ; Malaria, Falciparum/immunology ; Plasmodium falciparum/drug effects ; Plasmodium falciparum/immunology ; Pregnancy ; Pregnancy Complications, Parasitic/blood ; Pregnancy Complications, Parasitic/epidemiology ; Pregnancy Complications, Parasitic/immunology ; Young Adult
-
References:
-
Am J Trop Med Hyg. 2016 Mar;94(3):640-9. (PMID: 26711513)
PLoS One. 2014 Feb 04;9(2):e88173. (PMID: 24505415)
Infect Immun. 2018 Aug 22;86(9):. (PMID: 29986889)
J Immunol. 2010 Dec 15;185(12):7553-61. (PMID: 21078904)
Bull World Health Organ. 1983;61(6):1005-16. (PMID: 6370484)
Infect Immun. 2019 Jun 20;87(7):. (PMID: 30988054)
J Exp Med. 2004 Nov 1;200(9):1197-203. (PMID: 15520249)
PLoS One. 2012;7(6):e40049. (PMID: 22761948)
Lancet. 2004 Jan 24;363(9405):283-9. (PMID: 14751701)
Infect Immun. 2003 Nov;71(11):6620-3. (PMID: 14573685)
Malar J. 2014 Apr 30;13:162. (PMID: 24779545)
Science. 1996 Jun 7;272(5267):1502-4. (PMID: 8633247)
Mol Microbiol. 2003 Jul;49(1):179-91. (PMID: 12823820)
J Infect Dis. 2010 Jan 1;201(1):123-31. (PMID: 19954383)
EMBO Rep. 2005 Aug;6(8):775-81. (PMID: 16025132)
Bull Soc Pathol Exot. 2011 Oct;104(4):277-83. (PMID: 21818679)
Malar J. 2015 Dec 01;14:480. (PMID: 26626275)
Malar J. 2015 May 26;14:215. (PMID: 26006260)
Clin Vaccine Immunol. 2006 Dec;13(12):1307-13. (PMID: 17035513)
Open Forum Infect Dis. 2016 May 10;3(2):ofw092. (PMID: 28487863)
Clin Microbiol Rev. 2004 Oct;17(4):760-9, table of contents. (PMID: 15489346)
J Mol Biol. 2010 Apr 2;397(3):826-34. (PMID: 20109466)
Infect Immun. 2012 Apr;80(4):1479-90. (PMID: 22331427)
Malar J. 2018 Mar 9;17(1):106. (PMID: 29523137)
Mol Biochem Parasitol. 2007 Oct;155(2):103-12. (PMID: 17669514)
-
Substance Nomenclature:
-
0 (Antibodies, Protozoan)
0 (Antigens, Protozoan)
0 (Antimalarials)
0 (Drug Combinations)
0 (Immunoglobulin G)
0 (VAR2CSA protein, Plasmodium falciparum)
37338-39-9 (fanasil, pyrimethamine drug combination)
88463U4SM5 (Sulfadoxine)
Z3614QOX8W (Pyrimethamine)
-
Entry Date(s):
-
Date Created: 20200816 Date Completed: 20201013 Latest Revision: 20201013
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC7428160
-
DOI:
-
10.1371/journal.pone.0237671
-
PMID:
-
32797068
-
In high malaria transmission settings, the use of sulfadoxine-pyrimethamine-based intermittent preventive treatment during pregnancy (IPTp-SP) has resulted in decreased antibody (Ab) levels to VAR2CSA. However, information of Ab levels in areas of low or intermediate malaria transmission after long-term implementation of IPTp-SP is still lacking. The present study sought to evaluate antibody prevalence and levels in women at delivery in Etoudi, a peri-urban area in the capital of Yaoundé, Cameroon, that is a relatively low-malaria transmission area. Peripheral plasma samples from 130 pregnant women were collected at delivery and tested for IgG to the full-length recombinant VAR2CSA (FV2) and its most immunogenic subdomain, DBL5. The study was conducted between 2013 and 2015, approximately ten years after implementation of IPTp-SP in Cameroon. About 8.6% of the women attending the clinic had placental malaria (PM). One, two or 3 doses of SP did not impact significantly on either the percentage of women with Ab to FV2 and DBL5 or Ab levels in Ab-positive women compared to women not taking SP. The prevalence of Ab to FV2 and DBL5 was only 36.9% and 36.1%, respectively. Surprisingly, among women who had PM at delivery, only 61.5% and 57.7% had Ab to FV2 and DBL5, respectively, with only 52.9% and 47.1% in PM-positive paucigravidae and 77.7% of multigravidae having Ab to both antigens. These results suggest that long-term implementation of IPTp-SP in a low-malaria transmission area results in few women having Ab to VAR2CSA.
Competing Interests: The authors have declared that no competing interest exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.